Acumen Pharmaceuticals
Carmel
About Acumen Pharmaceuticals
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (A╬▓Os), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $330.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:ABOS
- Website: acumenpharm.com
- Phone: +1 6508757772
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/acumen-pharmaceuticals-12384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.